# US 2022/0017519 A1 · 7-BENZYL-4-(2-METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-a]PYRIDO[3,4-e]PYRIMIDIN-5(1H)-ONE, ANALOGS THEREOF, AND SALTS THEREOF AND METHODS FOR THEIR USE IN THERAPY

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017519 A1
- Document ID: US20220017519A1
- Status: Published application
- Kind: A1
- Application number: 17/357,008
- Filed: 2021-06-24
- Published: 2022-01-20
- Earliest claimed: 2015-01-30
- Assignees: Chimerix, Inc.
- Applicants: Chimerix, Inc.
- Inventors: Joshua E. ALLEN; Martin STOGNIEW; Richard S. POTTORF; Bhaskara Rao NALLAGANCHU; Gary OLSON; Yanjun SUN
- Web page: https://patentgrep.com/patent/US20220017519A1

## CPC

- C07D 471/14: Ortho-condensed systems
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/12: in which the condensed system contains three hetero rings
- C07D 487/14: Ortho-condensed systems
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10): as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.

## Claims

### Claim 1

A compound having formula (10)
or a pharmaceutically acceptable salt thereof; wherein R1 and R2 are independently selected from the group consisting of H, C1-4alkyl, C1-4alkylphenyl, C1-4alkylphenylketone, C1-4benzyl-piperazine, C1-4alkylthienyl, C1-4alkylpyridinyl, C1-4alkylisoxazolidinyl, C1-4alkylmorpholinyl, C1-4alkylthiazolyl, and C1-4alkylpyrazinyl wherein C1-4alkyl, C1-4alkylphenyl, C1-4alkylphenylketone, C1-4benzyl-piperazine, C1-4alkylthienyl, C1-4alkylpyridinyl, C1-4alkylisoxazolidinyl, C1-4alkylmorpholinyl, C1-4alkylthiazolyl, and C1-4alkylpyrazinyl are optionally substituted with C1-4alkyl, C1-4alkoxyl, hydroxyl, perhalogenated C1-4alkyl, or halogen, and wherein when R1 represents CH2Ph, R2 does not represent CH2-((2-CH3)-Ph.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 and/or R2 is a benzyl optionally substituted with one or more of the following substituents on the benzyl ring: X, —CH3, —NO2, —OCH3, —CN, —CXH2, —CX2H, C2-C4 alkyl, —CX3, —CH2(CX3), —CH(CX3)2, —C(CX3)3, —CpX2p+1, —OCX3, —OCpH2p+1, —OCpX2p+1, ORm, SRm, NRmRn, NRmC(O)Rn, SORm, SO2Rm, C(O)Rm, and C(O)ORm;
where Rm and Rn are independently selected from hydrogen or a C1-C4 alkyl;
where p is an integer from 2 to 20; and
X represents a halogen.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R1 is a hydrogen or an unsubstituted benzyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R2 is a substituted or an unsubstituted, heterocycloalkylalkyl.

### Claim 5 (depends on 4)

The compound of claim 4, wherein the substituted heterocycloalkylalkyl is a morpholinoalkyl or piperazinylalkyl group.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R2 is a substituted or an unsubstituted heteroarylalkyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound is represented by formula (40)
or a pharmaceutically acceptable salt thereof; wherein
wherein Ra1, Ra2, Ra3, Ra4, and Ra5 are each independently selected from the group consisting of hydrogen, X, —CH3, —NO2, —OCH3, —CN, —CXH2, —CX2H, C2-C4 alkyl, —CX3, —CH2(CX3), —CH(CX3)2, —C(CX3)3, —CpX2p+1, —OCX3, —OCpH2p+1, —OCpX2p+1, ORm, SRm, NRmRn, NRmC(O)Rn, SORm, SO2Rm, C(O)Rm, and C(O)ORm;
where Rm and Rn are independently selected from hydrogen or a C1-C4 alkyl;
p is an integer from 2 to 20; and
X represents a halogen.

### Claim 7 (depends on 5)

The compound of claim 5, wherein the substituted heteroarylalkyl is a pyridylalkyl or isoxazolidinylalkyl or group.

### Claim 9 (depends on 8)

The compound of claim 8, wherein R1 is a hydrogen.

### Claim 10 (depends on 8)

The compound of claim 8, wherein the compound is represented by formula (45)
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 8)

The compound of claim 8, wherein Ra3 is fluorine.

### Claim 12 (depends on 8)

The compound of claim 8, wherein Ra2 and Ra4 are fluorine.

### Claim 13 (depends on 1)

The compound of claim 1 having formula (50)
or a pharmaceutically acceptable salt thereof; wherein
Rb is selected from the group consisting of X, —CH3, —NO2, —OCH3, —CN, —CXH2, —CX2H, C2-C4 alkyl, —CX3, —CH2(CX3), —CH(CX3)2, —C(CX3)3, —CpX2p+1, —OCX3, —OCpH2p+1, —OCpX2p+1, ORm, SRm, NRmRn, NRmC(O)Rn, SORm, SO2Rm, C(O)Rm, and C(O)ORm;
Ra1, Ra2, Ra4, and Ra5 are each independently selected from the group consisting of hydrogen, X, —CH3, —NO2, —OCH3, —CN, —CXH2, —CX2H, C2-C4 alkyl, —CX3, —CH2(CX3), —CH(CX3)2, —C(CX3)3, —CpX2p+1, —OCX3, —OCpH2p+1, —OCpX2p+1, ORm, SRm, NRmRn, NRmC(O)Rn, SORm, SO2Rm, C(O)Rm, and C(O)ORm;
where Rm and Rn are independently selected from hydrogen or a C1-C4 alkyl;
p is an integer from 2 to 20;
and X represents a halogen.

### Claim 14 (depends on 13)

The compound of claim 13, wherein R1 is a hydrogen.

### Claim 15 (depends on 13)

The compound of claim 13, wherein the compound is represented by formula (55)
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 13)

The compound of claim 13, wherein Rb is a fluorine and Ra1 is a methyl.

### Claim 17 (depends on 13)

The compound of claim 13, wherein Rb and Ra2 are each selected from fluorine or chlorine.

### Claim 18 (depends on 13)

The compound of claim 13 having formula (60)
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 13)

The compound of claim 13, wherein Rb is a CH3 or a OCH3 substituent.

### Claim 20 (depends on 13)

The compound of claim 13, wherein Rb is Cl, and Ra1 is Cl.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A composition comprising a salt of a compound of any one of claims 1-20.

### Claim 22 (depends on 21)

The composition according to claim 21, wherein the salt comprises a counterion selected from the group consisting of: hydrochloride, hydrobromide, hydrogensulphate, sulfate, phosphate, fumarats, succinate, oxalates and lactates, bisulfate, hydroxyl, tartrate, nitrate, citrate, bitartrate, carbonate, malate, maleate, fumarate sulfonate, methylsulfonate, formate, acetate, and carboxylate, p-toluene-sulfonate, benzenesulfonate, methanesulfonate, oxalate, succinate, tartrate, citrate, fumarate, glucuronate, ascorbate and maleate, ammonium, sodium, potassium, calcium, magnesium, zinc, lithium, methylamino, dimethylamino, diethylamino and triethylamino.

### Claim 23 (depends on 21)

The composition according to claim 21, wherein the salt is a di-salt.

### Claim 24 (depends on 23)

The composition according to claim 23, wherein the di-salt is a hydrochloride di-salt.

### Claim 25 (depends on 23)

The composition according to claim 23, wherein the di-salt is a hydrobromide di-salt.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A pharmaceutical composition comprising a compound according to any one of claims 1-20 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A method of treatment, comprising administering to a subject in need of such treatment a pharmaceutically acceptable amount of a compound according to any one of claims 1-20 or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 27)

The method of claim 27, wherein the treatment is for a Non-Hodgkin's lymphoma or an acute leukemia.

### Claim 29 (depends on 27)

The method of claim 27, wherein the treatment is a salvage therapy.

### Claim 30 (depends on 27)

The method of claim 27, wherein the pharmaceutically acceptable amount of the compound is administered according to an infrequent dosing regimen.

### Claim 31 (depends on 27)

The method of claim 27, wherein the pharmaceutically acceptable amount of the compound or the pharmaceutically acceptable salt thereof is a dose ranging from about 100 mg to about 200 mg.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A method of treating a condition in a subject, comprising:
(i) administering to the subject the first therapeutic agent including a compound according to any one of claims 1-20 or a pharmaceutically acceptable salt thereof; and
(ii) monitoring level of the compound or a pharmaceutically acceptable salt thereof or a metabolite thereof in the subject using pharmacokinetic profiling

### Claim 33 (depends on 32)

The method of claim 32, wherein dosing of the compound or a pharmaceutically acceptable salt thereof is selected to maintain a maximum concentration of the compound or a pharmaceutically acceptable salt thereof in blood (whole blood, plasma, or serum) of the subject between about 85 ng/mL and 1500 ng/mL for a therapeutic time period.

### Claim 34 (depends on 32)

The method of claim 32, wherein dosing of the compound or a pharmaceutically acceptable salt thereof is selected to maintain an exposure of the compound or a pharmaceutically acceptable salt thereof over time as measured in blood (whole blood, plasma, or serum) of the subject between about 150 ng hr/mL and about 8000 ng hr/mL for a therapeutic time period.

### Claim 35 (depends on 32)

The method according to claim 32, further comprising administering the second therapeutic agent conditional on the level of the first therapeutic agent in the subject.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A method of treatment, comprising administering to a subject in need of such treatment:
(i) a first therapeutic agent including a compound according to any one of claims 1-20 or a pharmaceutically acceptable salt thereof in combination with (ii) a second therapeutic agent, wherein the first therapeutic agent and the second therapeutic agent are administered either simultaneously or sequentially.

### Claim 37

A method of treating a condition in a subject, comprising:
(i) over a first time interval, administering a plurality of doses of a therapeutic agent including compound (1):
an analog thereof, or a pharmaceutically acceptable salt of compound (1) or an analog thereof, wherein the plurality of doses is administered over a second time interval within the first time interval; and
(ii) repeating step (i) one or more additional times.

### Claim 38 (depends on 37)

The method of claim 37, wherein the condition is cancer.

### Claim 39 (depends on 37)

The method of claim 37, wherein the subject is a human.

### Claim 40 (depends on 37)

The method of claim 37, wherein the subject is a domesticated pet.

### Claim 41 (depends on 37)

The method of claim 37, wherein the therapeutic agent is compound (1) or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 37)

The method of claim 37, wherein the therapeutic agent is an analog of compound (1) or a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 42)

The method of claim 42, wherein the analog of compound (1) has the structure of compound (10).

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 43)

The method of claim 43, wherein the analog is a compound according to any one of claims 1-20 or a pharmaceutically acceptable salt thereof.

### Claim 45 (depends on 37)

The method of claim 37, further comprising the step of waiting for a predetermined waiting time between one or more repetitions of step (i).

### Claim 46 (depends on 45)

The method of claim 45, wherein the predetermined waiting time is the same length as the first time interval.

### Claim 47 (depends on 46)

The method of claim 46, wherein the pharmaceutically acceptable salt is a di-salt.

### Claim 48 (depends on 47)

The method of claim 47, wherein the di-salt is a hydrochloride di-salt.

### Claim 49 (depends on 37)

The method of claim 37, wherein the therapeutic agent is administered orally.

### Claim 50 (depends on 49)

The method of claim 49, wherein each oral dose ranges from about 1 mg to about 1000 mg.

### Claim 51 (depends on 37)

The method of claim 37, wherein the therapeutic agent is administered intravenously.

### Claim 52 (depends on 37)

The method of claim 37, wherein the therapeutic agent is administered topically.

### Claim 53 (depends on 37)

The method of claim 37, wherein the subject has received at least one prior therapy.

### Claim 54 (depends on 37)

The method of claim 37, wherein the first time interval is 7 days.

### Claim 55 (depends on 54)

The method of claim 54, wherein the second time interval is from two to five consecutive days.

### Claim 56 (depends on 55)

The method of claim 55, wherein the second time interval is two consecutive days.

### Claim 57 (depends on 55)

The method of claim 55, wherein the second time interval is three consecutive days.

### Claim 58 (depends on 54)

The method of claim 54, wherein the therapeutic agent is administered once daily within the second time interval.

### Claim 59 (depends on 54)

The method of claim 54, wherein the therapeutic agent is administered twice daily within the second time interval.

### Claim 60

A method of treating or preventing a disease or condition comprising: administering to a human or animal subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of compound (1):
or a pharmaceutically acceptable salt thereof.

### Claim 61 (depends on 60)

The method of claim 60, wherein the disease is a B-cell cancer.

### Claim 62 (depends on 61)

The method of claim 61, wherein the B-cell cancer is a multiple myeloma, B-cell lymphoma or a B-cell leukemia.

### Claim 63 (depends on 60)

The method of claim 60, wherein the disease is a pediatric cancer.

### Claim 64 (depends on 63)

The method of claim 63, wherein the subject is younger than 18, wherein is younger than 13 years old, or is younger than 5 years old.

### Claim 65 (depends on 60)

The method of claim 60, wherein the pediatric cancer is selected from the group consisting of pediatric solid tumors, pediatric sarcomas, pediatric Ewing's sarcomas, pediatric gliomas, pediatric central nervous system cancers, pediatric leukemia and pediatric lymphoma.

### Claim 66 (depends on 60)

The method of claim 60, where the disease or condition prevented or treated is metastases.

### Claim 67 (depends on 60)

The method of claim 60, wherein the condition is pain.

### Claim 68 (depends on 60)

The method of claim 60, wherein the condition is edema.

### Claim 69 (depends on 60)

The method of claim 60, wherein the condition is hemiplegia.

### Claim 70 (depends on 60)

The method of claim 60, wherein the disease is a lymphadenopathy.

### Claim 71 (depends on 60)

The method of claim 60, wherein the disease is a cancer and the treatment does not cause severe or serious adverse events.

### Claim 72 (depends on 60)

The method of claim 60, wherein the disease is a cancer and the treatment does not cause peripheral neuropathy.

### Claim 73 (depends on 60)

The method of claim 60, wherein the disease is a cancer and the treatment does not cause cardiotoxicity.

### Claim 74

A method of treating or preventing a disease or condition comprising: administering to a human or animal subject in need of such treatment a pharmaceutical composition comprising an effective amount of compound (1):
or a pharmaceutically acceptable salt thereof, wherein the effective amount of compound (1) or the pharmaceutically acceptable salt thereof is a dose ranging from about 125 mg to about 625 mg.

### Claim 75 (depends on 74)

The method of claim 74, wherein the dose of compound (1) or the pharmaceutically acceptable salt thereof ranges from about 250 mg to about 625 mg.

### Claim 76 (depends on 75)

The method of claim 75, wherein the dose of compound (1) or the pharmaceutically acceptable salt thereof ranges from about 375 mg to about 625 mg.

### Claim 77 (depends on 76)

The method of claim 76, wherein the dose of compound (1) or the pharmaceutically acceptable salt thereof ranges from about 500 mg to about 625 mg

### Claim 78 (depends on 77)

The method of claim 77, wherein the dose of compound (1) or the pharmaceutically acceptable salt thereof is about 625 mg.

### Claim 79 (depends on 74)

The method of claim 74, where the dosage is based on compound (1) in its free base form.

### Claim 80 (depends on 74)

The method of claim 74, wherein the pharmaceutical composition is administered twice a day.

### Claim 81 (depends on 74)

The method of claim 74, wherein the pharmaceutical composition is administered daily, continuously or without intermittent periods of withholding drug administration.

### Claim 82 (depends on 74)

The method of claim 74, wherein the pharmaceutical composition is administered twice per week or once per week.

### Claim 83 (depends on 74)

The method of claim 74, wherein the pharmaceutical composition is administered once every two weeks, once every three weeks, or once every four weeks.

### Claim 84 (depends on 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The method according to any one of claims 74-83, further comprising the step of administering a second therapeutic agent, wherein compound (1) or the pharmaceutically acceptable salt thereof is administered before, simultaneously, or after the second therapeutic agent.

### Claim 85

A method of treating a disease or condition in a human or animal subject in need of such treatment, the method comprising:
(i) administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of compound (1):
or a pharmaceutically acceptable salt thereof; and
(ii) monitoring levels of compound (1), the pharmaceutically acceptable salt thereof, or a metabolite thereof in the subject using pharmacokinetic profiling, wherein dosing of compound (1) or a pharmaceutically acceptable salt thereof is selected to maintain a concentration of compound (1), the pharmaceutically acceptable salt thereof, or the metabolite thereof in whole blood, plasma, serum, or cerebrospinal fluid of the subject is at least about 400 ng/mL for a therapeutic time period within 4 hours post-treatment.

### Claim 86 (depends on 85)

The method of claim 85, wherein the concentration is at least about 1,500 ng/mL.

### Claim 87 (depends on 85)

The method of claim 85, wherein the concentration is between about 400 to 8,000 ng/mL

### Claim 88 (depends on 85)

The method of claim 85, wherein the concentration is between about 1,500 to 8,000 ng/mL.

### Claim 89

A method of treating a disease or condition in a human or animal subject in need of such treatment, the method comprising:
(i) administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of compound (1):
or a pharmaceutically acceptable salt thereof; and
(ii) monitoring levels of compound (1), the pharmaceutically acceptable salt thereof, or a metabolite thereof in the subject using pharmacokinetic profiling, wherein dosing of compound (1) or a pharmaceutically acceptable salt thereof is selected to obtain an AUC of compound (1), the pharmaceutically acceptable salt thereof, or the metabolite thereof in whole blood, plasma, serum, or cerebrospinal fluid of the subject is at least about 3,500 hr-ng/mL with a time period of 24 or 48 hours post-treatment or extrapolated to infinity.

### Claim 90 (depends on 89)

The method of claim 89, wherein the AUC is at least about 15,000 hr-ng/mL.

### Claim 91 (depends on 89)

The method of claim 89, wherein the AUC is between about 3,500 and 65,000 hr-ng/mL.

### Claim 92 (depends on 89)

The method of claim 89, wherein the AUC is between about 15,000 and 65,000 hr-ng/mL.

### Claim 93

A method of treating a disease or condition in a human or animal subject in need of such treatment, the method comprising:
(i) administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of compound (1):
or a pharmaceutically acceptable salt thereof; and
(ii) monitoring levels of compound (1), the pharmaceutically acceptable salt thereof, or a metabolite thereof in the subject using pharmacokinetic profiling,
wherein dosing of compound (1) or a pharmaceutically acceptable salt thereof is selected to result in undetectable concentrations of compound (1), the pharmaceutically acceptable salt thereof, or the metabolite thereof in whole blood, plasma, serum, or cerebrospinal fluid of the subject at 3 days, 4 days, 5 days, 6 days, or 7 days post-treatment.

### Claim 94 (depends on 85, 86, 87, 88, 89, 90, 91, 92, 93)

The method according to any one of claims 85-93, wherein the metabolite is selected from monohydroxylated or dihydroxylated compound (1).

### Claim 95

A method of treating or preventing a disease, disorder, or condition comprising: administering to a human or animal subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of compound (1):
or a pharmaceutically acceptable salt thereof.

### Claim 96 (depends on 95)

The method of claim 95, wherein the disease is prostate cancer or endometrial cancer.

### Claim 97 (depends on 95)

The method of claim 95, wherein the disorder is psychosis.

### Claim 98 (depends on 95)

The method of claim 95, wherein the disorder is a CNS disorder.

### Claim 99 (depends on 95)

The method of claim 95, wherein the disorder or disease is associated with dysregulated dopamine signaling.

### Claim 100 (depends on 95)

The method of claim 95, wherein the disorder Tourette syndrome.

### Claim 101 (depends on 100)

The method of claim 100, wherein the subject suffers from nausea or emesis.

### Claim 102 (depends on 95)

The method of claim 95, wherein the disorder is schizophrenia or bipolar disorder.

### Claim 103 (depends on 95)

The method of claim 95, wherein the disorder is anxiety.

### Claim 104 (depends on 95)

The method of claim 95, wherein the disorder is hypotension.

### Claim 105 (depends on 95)

The method of claim 95, wherein the disease is a virus.

### Claim 106 (depends on 105)

The method of claim 105, wherein the virus is an RNA virus, DNA virus, or retroviruses.

### Claim 107 (depends on 105)

The method of claim 105, wherein the virus is selected from the group consisting of influenza A virus including subtype H1N1, influenza B virus, influenza C virus, rotavirus A, rotavirus B, rotavirus C, rotavirus D, rotavirus E, SARS coronavirus, human adenovirus types (HAdV-1 to 55), human papillomavirus (HPV) Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, parvovirus B19, molluscum contagiosum virus, JC virus (JCV), BK virus, Merkel cell polyomavirus, coxsackie A virus, norovirus, Rubella virus, lymphocytic choriomeningitis virus (LCMV), yellow fever virus, measles virus, mumps virus, respiratory syncytial virus, rinderpest virus, California encephalitis virus, hantavirus, rabies virus, ebola virus, marburg virus, herpes simplex virus-1 (HSV-1), herpes simplex virus-2 (HSV-2), varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes lymphotropic virus, roseolovirus, Kaposi's sarcoma-associated herpesvirus, hepatitis A (HAV), hepatitis B (HBV), hepatitis C (HCV), hepatitis D (HDV), hepatitis E (HEV), humanimmunodeficiency virus (HIV), The Human T-lymphotropic virus Type I (HTLV-1), Friend spleen focus-forming virus (SFFV) or Xenotropic MuLV-Related Virus (XMRV).

### Claim 108 (depends on 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The method according to any one of claims 95-107, further comprising the step of administering a second therapeutic agent, wherein compound (1) or salt thereof is administered before, simultaneously, or after the second therapeutic agent.

### Claim 109 (depends on 108)

The method of claim 108, wherein the administration of compound (1) or salt thereof and the administration of the second therapeutic agent are separated by a time interval of at least one day, at least two days, or at least three days.

### Claim 110 (depends on 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The method according to any one of claims 95-107, further comprising assaying cleaved cytokeratin-18 in a sample obtained from the subject.

### Claim 111 (depends on 110)

The method of claim 110, wherein the cleaved cytokeratin-18 is measured from blood from the subject using a M30 ELISA assay.

### Claim 112 (depends on 48, 49)

The method of either claim 48 or claim 49, determining whether cleaved cytokeratin-18 has increased upon treatment with compound (1) or salt thereof.

### Claim 113 (depends on 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The method according to any one of claims 95-107, further comprising assaying total cytokeratin-18 in a sample obtained from the subject.

### Claim 114 (depends on 113)

The method of claim 113, wherein the cleaved cytokeratin-18 is measured from blood from the subject using a M65 ELISA assay.

### Claim 115 (depends on 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The method according to any one of claims 95-107, comprising assaying both cleaved and total cytokeratin-18 in the sample obtained from the subject.

### Claim 116 (depends on 115)

The method of claim 115, where is the sample is obtained on days 1-21, 2-21, 7-21, 14-21, or 21 after administering compound (1) or salt thereof.

### Claim 117 (depends on 115)

The method of claim 115, continuing the treatment of the subject with compound (1) or salt thereof, if there is a disproportionate increase in the amount of cleaved cytokeratin 18 relative to total cytokeratin 18.

### Claim 118

A method of identifying whether a subject having cancer is likely to be responsive to administration of compound (1), comprising:
(i) obtaining a biological sample from the subject;
(ii) measuring expression, post-translational modifications, or activity levels of or mutations in eIF2-alpha, ATF4, CHOP, or DR5 in the sample;
(iii) comparing the levels measured and/or the mutations found in the sample to those for a pre-determined standard; and
(iv) determining whether the subject is likely to be responsive to administration of compound (1), based on the levels measured and/or mutations found in the sample to those for the pre-determined standard.

### Claim 119

A method of assessing the effectiveness of or monitoring a subject having cancer and undergoing administration of compound (1), comprising:
(i) obtaining a biological sample from the subject;
(ii) measuring expression, post-translational modifications, or activity levels of or mutations in eIF2-alpha, ATF4, CHOP, DR5, or cleaved or total cytokeratin 18 in the sample;
(iii) comparing the levels measured and/or the mutations found in the sample to those for a pre-determined standard; and
(iv) determining whether the subject is responsive to administration of compound (1), based on the levels measured and/or mutations found in the sample to those for the pre-determined standard.

### Claim 120

A method of identifying whether a subject having cancer is likely to be responsive to administration of compound (1), comprising:
(i) obtaining a biological sample from the subject;
(ii) measuring expression, post-translational modifications, or activity levels of or mutations in at least one dopamine receptor in the sample;
(iii) comparing the levels measured and/or the mutations found in the sample to those for a pre-determined standard; and
(iv) determining whether the subject is likely to be responsive to administration of compound (1), based on the levels measured and/or mutations found in the sample to those for the pre-determined standard.

### Claim 121 (depends on 120)

The method of claim 120, wherein the dopamine receptor is selected from DRD2, DRD2S, DRD2L, and DRD3.

### Claim 122 (depends on 120)

The method of claim 120, wherein the dopamine receptor is from the D2-like family of dopamine receptors.

### Claim 123 (depends on 120)

The method of of claim 120, further comprising the step of administering an effective amount of compound (1) to the subject.

### Claim 124

A method of assessing the effectiveness of or monitoring a subject having cancer and undergoing administration of compound (1), comprising:
(i) obtaining a biological sample from the subject;
(ii) measuring expression, post-translational modifications, or activity levels of or mutations in at least one dopamine receptor in the sample;
(iii) comparing the levels measured and/or the mutations found in the sample to those for a pre-determined standard; and
(iv) determining whether the subject is responsive to administration of compound (1), based on the levels measured and/or mutations found in the sample to those for the pre-determined standard.

### Claim 125 (depends on 124)

The method of claim 124, wherein the dopamine receptor is selected from DRD2, DRD2S, DRD2L, and DRD3.

### Claim 126 (depends on 124)

The method of claim 124, wherein the dopamine receptor is from the D2-like family of dopamine receptors.

### Claim 127

A method for screening a potential cancer therapeutic, comprising:
(i) contacting at least one G protein-coupled receptor (GPCR) with a test compound suspected of being a cancer therapeutic;
(ii) measuring the binding affinity, interaction or GPCR signalling of the test compound to the GPCR; and
(iii) comparing the binding affinity or interaction of test compound to a pre determined threshold, wherein GPCR antagonism or GPCR signaling antagonism of the test compound comparable to or greater than the threshold is indicative of a cancer therapeutic.

### Claim 128

A method for screening a potential cancer therapeutic, comprising:
(i) contacting at least one dopamine receptor with a test compound suspected of being a cancer therapeutic;
(ii) measuring the binding affinity or interaction of the test compound to the at least one dopamine receptor; and
(iii) comparing the binding affinity or interaction of the test compound to a pre determined threshold, wherein inhibition of the at least one dopamine receptor by the test compound comparable to or greater than the threshold is indicative of a cancer therapeutic.

### Claim 129 (depends on 128)

The method of claim 128, wherein the dopamine receptor is selected from DRD2, DRD2S, DRD2L, and DRD3.

### Claim 130 (depends on 128)

The method of claim 128, wherein inhibition of the D2-like family of dopamine receptors is indicative of a cancer therapeutic.

### Claim 131 (depends on 128)

The method of claim 128, wherein inhibition of both DRD2 and DRD3 dopamine receptors is indicative of a cancer therapeutic.

### Claim 132 (depends on 128, 129, 130, 131)

The method according to any one of claims 128-131, wherein the pre-determined threshold is the inhibition of the at least one dopamine receptor by compound (1).

### Claim 133

A method for screening a potential cancer therapeutic using a processor, comprising:
(i) using a computational docking method to model binding or interaction, if any, of one or more 3-dimensional structures of a test molecule suspected of being a cancer therapeutic to a 3-dimensional structure or model of at least one dopamine receptor;
(ii) using the computational method to estimate the binding affinity or interaction of the test molecule structure to the structure of the at least one dopamine receptor; and
(iii) using the computational method to compare the binding affinity or interaction of the test molecule to a pre-determined threshold, wherein inhibition of the at least one dopamine receptor by the test compound comparable to or greater than the threshold is indicative of a cancer therapeutic.

### Claim 134 (depends on 133)

The method of claim 133, wherein the dopamine receptor is selected from DRD2, DRD2S, DRD2L, and DRD3.

### Claim 135 (depends on 133)

The method of claim 133, wherein inhibition of the D2-like family of dopamine receptors is indicative of a cancer therapeutic.

### Claim 136 (depends on 133)

The method of claim 133, wherein inhibition of both DRD2 and DRD3 dopamine receptors is indicative of a cancer therapeutic.

### Claim 137 (depends on 133, 134, 135, 136)

The method according to any one of claims 133-136, wherein the pre-determined threshold is the inhibition of the at least one dopamine receptor by compound (1).

### Claim 138

A method of identifying whether a subject having cancer is likely to be responsive to administration of compound (1), comprising:
(i) obtaining a biological sample from the subject;
(ii) measuring prolactin levels;
(iii) determining whether the subject is likely to be responsive to administration of compound (1), based on the levels measured relative to those for a pre-determined standard.

### Claim 139

A method of assessing the effectiveness of or monitoring a subject having cancer and undergoing administration of compound (1), comprising:
(i) obtaining a biological sample from the subject;
(ii) measuring prolactin levels;
(iii) determining whether the subject is likely to be responsive to administration of compound (1), based on the levels measured relative to those for a pre-determined standard.

### Claim 140

A method for screening a potential cancer therapeutic that induces prolactin in pituitary cells or causes prolactin secretion into the peripheral blood.

### Claim 141

A method of treatment comprising administering a compound that induces prolactin in pituitary cells or causes prolactin secretion into the peripheral blood.
